Cancer
MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
Published in Drug Week, May 4th, 2007
MedImmune, Inc. (NASDAQ:MEDI) and Micromet, Inc. (NASDAQ:MITI) announced that published proof-of-concept data with a new BiTE(R) molecule (bscEphA2xCD3) show that the compound killed tumor cells at dose levels considerably below those required by classical monoclonal antibody-based therapies. The in vitro and in vivo data, collected from cell culture experiments conducted under the companies' BiTE(R) technology research collaboration, were published in the April 15, 2007 issue of Cancer Research.
BiTE molecules represent a novel class of drugs that function as bi- specific T-cell engagers. They are unique in their ability to enable the body's killer T cells to recognize...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-05-04)
More Articles from Drug Week
- Acute Lymphoblastic Leukemia
Progress toward a targeted therapy for a specific form of leukemia - Addiction Medicine
Brief physician interventions have impact on problem drinking - Addiction Medicine
UCSF launches study on treatment for prescription drug addiction - Alzheimer Disease
Research could lead to treatment for Alzheimer's disease - Amyotrophic Lateral Sclerosis
Diseased Brain Cells Involved In ALS Motor Neuron Death - Anemia
Study produces conflicting findings on the use of anti-anemia drug in cancer patients - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
